Classic triple therapy of Helicobacter pylori eradication still an effective treatment in Eastern Anatolia

Yıl 2012, Cilt: 11 Sayı: 1, 24 - 28, 01.04.2012

Ahmet Uyanıkoğlu Muharrem Coşkun Doğan Nasır Binici

Öz

Background and Aims: For Helicobacter pylori eradication, proton pump inhibitor -based triple therapy is recommended as the first-line therapy. This classic treatment has been reported to be ineffective, in particular with development of clarithromycin resistance. The aim of this study was to evaluate the efficiency of the classic triple therapy as the first line of eradication. Materials and Methods: This prospective study included patients seen between February 2010 and July 2011, with endoscopic biopsy-detected Helicobacter pylori who were previously untreated with a first-line therapy and who accepted to participate in the study, with at least 90% drug usage. The treatment protocol included clarithromycin, amoxicillin and proton pump inhibitorfor 14 days as 2x1, and 1x1 continuation of lansoprazole for two months. Successful eradication of Helicobacter pylori was considered as eradication of Helicobacter pylori antigen in the stool for control patients who completed the treatment. Patients with erosion and ulcer were considered as peptic ulcer patients and others as having non-ulcer dyspepsia. Results: 104 patients with biopsyproven and gastroscopic-identified Helicobacter pylori completed the study. 51 (49%) patients were male, with a mean age of 39.98±12.82 years (range: 13-73). 60 (57%) patients had peptic ulcer and 44 (43%) had non-ulcer dyspepsia. Helicobacter pylori antigen negativity was determined in 101 patients (97%). Helicobacter pylori was not eradicated in 3 patients: 2 peptic ulcer disease patients (1 erosive gastritis, 1 duodenal ulcer) and 1 non-ulcer dyspepsia patient (erythematous gastritis). Conclusions: For Helicobacter pylori eradication in the eastern region, the classic triple therapy resulted in 97% eradication, and thus this therapy remains the first to be proposed in primary care.

Anahtar Kelimeler

Helicobacter pylori, eradication, therapy

Helikobakter pilori eradikasyonunda klasik 3'lü tedavi Doğu Anadolu bölgesinde halen etkilidir

Öz

Amaç: Helikobakter pilori eradikasyonunda, proton pompa inhibitörübazlı üçlü tedavi birinci basamak tedavisi olarak önerilmektedir. Bu klasik tedavinin, özellikle klaritromisin direnci geliştiğinden etkisiz olduğuna dair yayınlar çıkmıştır. Bu çalışmada klasik üçlü tedavinin birinci basamakta etkinliği araştırılmıştır. Materyal ve Metod: Şubat 2010 Temmuz 2011 tarihleri arasında endoskopik biyopsisinde Helikobakter pilori saptanan, daha önce 1. basamak tedavi almayan, çalışmaya katılmayı kabul edip, ilaçların en az %90'ını kullanan hastalar prospektif olarak takip edildi. Tedavi protokolü olarak klaritromisin, amoksisilin ve proton pompa inhibitöründen oluşan hazır 3'lü tedavi paketi 2x1 14 gün, devamında 1x1 2 ay lansoprazol verilmiştir. Tedaviyi tamamlayan hastalarda eradikasyon kontrolü için gaitada Helikobakter pilori antijeni bakılmış, negatif gelen hastalarda eradikasyon başarılı kabul edilmiştir. Erozyon ve ülser rapor edilen hastalar peptik ülser, diğerleri non-ülser dispepsi olarak kabul edilmiştir. Bulgular: Gastroskopik biyopsi sonucu Helikobakter pilori pozitif saptanan ve çalışmayı tamamlayan 104 hastanın 51'i (%49) erkek, yaş ortalaması 39.98±12.82 (dağılım 13-73) idi. Hastalardan 60'ı (%57) peptik ülser, 44'ü (%43) non-ülser dispepsi idi. Hastalardan 101'inde (%97) kontrol Helikobakter pilori antijeni negatif saptanmıştır. Eradike olmayan 3 hastadan ikisi peptik ülser (1 eroziv gastrit, 1 duodenal ülser), biri de non-ülser dispepsi (eritemli gastrit) idi. Sonuç: Doğu Anadolu bölgesinde Helikobakter pilori eradikasyonunda, klasik 3'lü tedaviyle %97 eradikasyon sağlanmış olup, birinci basamakta halen ilk önerilecek tedavidir.

Anahtar Kelimeler

Helikobakter pilori, eradikasyon, tedavi

Kaynakça

• Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate
• and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med 2011;6. doi: 10.3402/ljm.v6i0.8412. Epub 2011 Sep 8.
• Rathbone M, Rathbone B. Helicobacter pylori and gastric cancer. Recent Results Cancer Res. 2011;185:83-97.
• Vizzardi E, Bonadei I, Piovanelli B, et al. Helicobacter pylori and isc- hemic heart disease. Panminerva Med 2011;53:193-202.
• Malfertheiner MV, Kandulski A, Schreiber J, Malfertheiner P. Heli- cobacter pylori infection and the respiratory system: A systematic review of the literature. Digestion 2011;84:212-20.
• Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association bet- ween
• Helicobacter pylori infection and insulin resistance: a syste
• matic review. Helicobacter 2011;16:79-88.
• Sato K, Ozawa K. The role of Helicobacter pylori infection in hema- tological diseases - a review. Gan To Kagaku Ryoho 2011;38:358- 61.
• Kato M, Ono S, Mabe K, et al. The significance of H. pylori eradi- cation in NSAIDs ulcer. Nihon Rinsho 2011;69:1049-56.
• Coşkun M, Dobrucalı A. Non-steroid anti-inflamatuar ilaçlar ve He- licobacter pylori [Non-steroid anti-inflammatory drugs and Helico- bacter pylori]. Turkiye Klinikleri J Int Med Sci 2005;1:26-8.
• Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helico- bacter pylori infection and public health implications. Helicobacter 2011;16(Suppl 1):1-9.
• Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gu. 2007;56:772-81.
• Uyanıkoğlu A, Coşkun M, Binici DN. Doğu Anadolu Bölgesinde üst gastrointestinal sistem kanser sıklığı ve dağılımı. Turk J Gastroente- rol 2010;21(Suppl 1) P304, S190.
• Uyanıkoğlu A, Coşkun M, Binici DN, et al. Doğu Anadolu Bölgesin- de Helicobacter pylori sıklığı [The Frequency of Helicobacter pylori in Eastern Anatolia]. Turk J Gastroenterol 2011;22 (Suppl 1):P39, S136.
• Dzieniszewski J, Jarosz M. Guidelines in the medical treatment of Helicobacter pylori infection. J Physiol Pharmacol 2006;57(Suppl 3):143-54.
• Demir M, Ataseven H. The effects of sequential treatment as a first-line therapy for Helicobacter pylori eradication. Turk J Med Sci 2011;41:427-33.
• De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarit- hromycin Resistance Observational (MICRO) Study. J Gastrointes- tin Liver Dis 2011;20:235-9.
• Özdil K, Çalhan T, Şahin A, et al. Levofloxacin based sequential and triple therapy compared with standart plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011; 58:1148-52. doi: 10.5754/hge11075.
• Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the effi- cacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Kore- a. Aliment Pharmacol Ther 2011;34:1098-105.
• Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
• Sezikli M, Çetinkaya ZA, Guzelbulut F, et al. Supplementing Vita- mins C and E to standard triple therapy for the eradication of He- licobacter pylori. J Clin Pharm Ther 2011 Jul 11. doi: 10.1111/j. 1365-2710.2011.01286.x.
• Ermis F, Akyuz F, Uyanikoglu A, et al. Second-line levofloxacin-ba- sed triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 2011;104:579-83.
• Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565-70.
• Toros AB, Ince AT, Kesici B, et al. A new modified concomitant the- rapy for Helicobacter pylori eradication in Turkey. Helicobacter 2011;16:225-8.
• Dixon MF, Genta RM, Yardley JH, Correa P. Classification and gra- ding of gastritis. The updated Sydney System. International Work- shop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
• Takao T, Ishikawa T, Ando T, et al. Multifaceted assessment of chronic gastritis: A study of correlations between serological, en- doscopic, and histological diagnostics. Gastroenterol Res Pract 2011;2011:631461.
• Genta RM, Spechler SJ, Kielhorn AF. The Los Angeles and Savary- Miller systems for grading esophagitis: utilization and correlation with histology. Dis Esophagus 2011;24:10-7.
• Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton-pump inhibitor-based therapy in Korea: a prospective randomized study. J Gastroenterol Hepatol 2012;27: 504-9. doi: 10.1111/j.1440-1746.2011.06922.x.
• Liu G, Xu X, He L, et al. Primary antibiotic resistance of Helicobac- ter pylori isolated from Beijing children. Helicobacter 2011;16:356- 62.
• Karczewska E, Wojtas-Bonior I, Sito E, et al. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resis- tance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011;63:799-807.
• Adın Y, Nazlıgül Y, Yeniova AÖ, et al. The efficacy of levofloxacin- based triple therapy for first-line Helicobacter pylori eradication. Dicle Medical Journal 2011;38:197-201.
• Uyanıkoğlu A, Davutoglu C, Togan M, Gültepe İ. Ranitidin bizmut sitrat ve klaritromisin ile alternatif Helicobacter pylori tedavisi. İs- tanbul Tip Derg 2008;71:61-4
• Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol 2011;26(Suppl 3):42-5.
• Fock KM. Functional dyspepsia, H. pylori and post infectious FD. J Gastroenterol Hepatol 2011;26(Suppl 3):39-41.
• Qian B, Ma S, Shang L, et al. Effects of Helicobacter pylori eradica- tion on gastroesophageal reflux disease. Helicobacter 2011;16: 255-65.
• Turkay C, Erbayrak M, Bavbek N, et al. Helicobacter pylori and his- topathological findings in patients with dyspepsia. Turk J Gastro- enterol 2011;22:122-7.
• Kilciler G, Polat Z, Uygun A, et al. The effect of Helicobacter pylo- ri eradication on atrophic gastritis and intestinal metaplasia. J Clin Anal Med 2011;2:17-20